2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
1. Evaluate the feasibility of ESS for detection of field cancerization in BE patients. 2. Investigate the biological background of field cancerization by studying: a) (ultra)structural changes in the tissue and b) genetic abnormalities and clonal…